Emily Rollins - 12 Mar 2024 Form 4 Insider Report for Science 37 Holdings, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
12 Mar 2024, 10:06:36 UTC
Prior SEC filing
05 Mar 2024
Next SEC filing
12 Nov 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christine Pellizzari, Attorney-in-fact for Emily Rollins

Key filing fact

Emily Rollins filed Form 4 for Science 37 Holdings, Inc. on 12 Mar 2024.

Key facts

  • This page summarizes Emily Rollins's Form 4 filing for Science 37 Holdings, Inc..
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 12 Mar 2024, 10:06.

Change

  • Previous filing in this sequence was filed on 05 Mar 2024.
  • Current net transaction value: -$11,788.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNCE transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$11,788
Shares
-2,050
Change %
-100%
Price
$5.75
Shares after
0
Date
12 Mar 2024
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNCE transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares
-24,742
Change %
-100%
Price
Shares after
0
Date
12 Mar 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
24,742
Exercise price
Footnotes
F2, F3
SNCE transaction Derivative

Stock Option

Disposed to Issuer

Transaction value
Shares
-1,378
Change %
-100%
Price
Shares after
0
Date
12 Mar 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,378
Exercise price
$201.00
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Emily Rollins is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 28, 2024, among the Issuer, eMed, LLC, a Delaware limited liability company ("Parent"), and Marlin Merger Sub Corporation, a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer ("Issuer Common Stock") at a purchase price of $5.75 per share, without interest and subject to applicable withholding taxes (the "Offer Price"). After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of March 12, 2024 (such date and time of such merger, the "Effective Time"). These shares of Issuer Common Stock were tendered for purchase pursuant to the tender offer.

Footnote F2

Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Issuer Common Stock upon vesting of the RSU.

Footnote F3

Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Issuer Common Stock subject to such RSU.

Footnote F4

Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Issuer Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

SEC remarks

On December 8, 2023, the Issuer effected a reverse stock split of Issuer Common Stock at a ratio of 1-for-20 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Issuer Common Stock, and the exercise price and shares of Issuer Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .